Nanobiotix appears to be a pre-commercial radiobiology asset whose revenue is contract-driven rather than product-driven: the top line swung from $32.9M in 2023Q4 to negative $16.5M in 2024Q4 and $3.7M in 2026Q2, an 86.1% year-over-year decline, while R&D and ...
Price trend, volume and key moving averages
Trailing total returns as of 10/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Sep 29, 2026 | -$0.80-64.7% vs -$0.48 | $6M+268.9% vs $2M |
Q2 2026 Mar 31, 2026 | -$0.46-250.7% vs $0.30 | $4M-93.2% vs $52M |
Q4 2025 Sep 30, 2025 | -$0.13+45.9% vs -$0.25 | $31M+31.2% vs $24M |
Q2 2025 Apr 2, 2025 | -$1.01-63.5% vs -$0.62 | $22M-709.2% vs $4M |
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients' prior course of radiotherapy Investigators concluded that JNJ-1900 (NBTXR3 may permit clinically meaningful local control using a substantially lower re-irradiation dose than patients' prior course of radiotherapy Enrollment in the dose-escalation and expansion parts of the study is complete per protocol; following the encourage findings, additional patient enrollment in this study is planned Data presented at the IASLC 2026 World Conference on Lung Cancer PARIS and CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated safety and efficacy data from the completed dose-escalation and expansion phases of a Phase 1 study sponsored by The University of Texas MD Anderson Cancer Center (“UT MD Anderson”) evaluating radiotherapy-activated JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiation (“reRT”).
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that Company management will participate in a fireside chat at the following investment conference:
Benchmark NBTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nanobiotix S.A. (NBTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $27.90 | $1.41B | -49.25 | 512.28% | -80.83% | — | — | |
| $15.92 | $1.84B | -13.05 | 8.28% | -21.25% | -44% | — | |
| $0.27 | $31.79M | -17.24 | 2.68% | -12.24% | -99.04% | — | |
| $9.96 | $416.27M | -6.00 | 56.89% | -225.34% | -165.83% | — | |
| $0.74 | $2.67M | -0.16 | -67.7% | -1578.79% | -91.95% | — | |
| $75.13 | $3.66B | -19.88 | — | — | -350.78% | — |
Nanobiotix S.A. (NBTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NBTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nanobiotix S.A. (NBTX) stock FAQ — growth, dividends, profitability & financials explained
Nanobiotix S.A. (NBTX) reported $16.9M in revenue for fiscal year 2025. This represents a 1139% increase from $1.4M in 2011.
Nanobiotix S.A. (NBTX) grew revenue by 512.3% over the past year. This is strong growth.
Nanobiotix S.A. (NBTX) reported a net loss of $105.0M for fiscal year 2025.
Nanobiotix S.A. (NBTX) had negative free cash flow of $71.0M in fiscal year 2025, likely due to heavy capital investments.
